Preferred Label : Teclistamab;
NCIt synonyms : Teclistamab-cqyv;
NCIt definition : A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen,
and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA)
expressed on plasma cells, with potential antineoplastic activity. Upon administration,
teclistamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells.
This results in the cross-linking of T-cells and tumor cells, and induces a potent
cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA,
a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed
on malignant plasma cells, plays a key role in promoting plasma cell survival.;
UNII : 54534MX6Z9;
CAS number : 2119595-80-9; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2119595-80-9
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Tecvayli;
Molecule name : JNJ 64007957; JNJ-64007957;
NCI Metathesaurus CUI : CL524654;
Codes from synonyms : 65150;
Origin ID : C136823;
UMLS CUI : C5235398;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
https://ansm.sante.fr/tableau-marr/teclistamab
2024
false
false
false
France
French
popular works
drug information
Teclistamab
risk management
teclistamab
---
https://ansm.sante.fr/tableau-acces-derogatoire/teclistamab
2023
false
false
false
France
French
drug information
Teclistamab
adult
multiple myeloma
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
summary of product characteristics
package leaflet
antibodies, monoclonal
Antineoplastic Agents, Immunological
teclistamab
---
https://www.has-sante.fr/jcms/p_3463441/fr/tecvayli-teclistamab-myelome-multiple
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
Triple-Class Refractory Multiple Myeloma
Recurrent Multiple Myeloma
adult
Antineoplastic Agents, Immunological
bispecific monoclonal antibodies
teclistamab
evaluation of the transparency committee
multiple myeloma
Teclistamab
---
https://www.has-sante.fr/jcms/p_3424344/fr/tecvayli-teclistamab-myelome-multiple
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
Triple-Class Refractory Multiple Myeloma
adult
antibodies, monoclonal
Teclistamab
injections, subcutaneous
Antineoplastic Agents, Immunological
teclistamab
evaluation of the transparency committee
multiple myeloma
---
https://www.ema.europa.eu/en/medicines/human/EPAR/tecvayli
2022
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Teclistamab
Teclistamab
antibodies, monoclonal
antibodies, monoclonal
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
multiple myeloma
teclistamab
injections, subcutaneous
drug interactions
pregnancy
breast feeding
Triple-Class Refractory Multiple Myeloma
recurrence
product surveillance, postmarketing
bispecific monoclonal antibodies
bispecific monoclonal antibodies
b-cell maturation antigen
CD3 Complex
---
https://www.has-sante.fr/jcms/p_3368649/fr/tecvayli-teclistamab-myelome-multiple
2022
false
false
false
France
multiple myeloma
antibodies, monoclonal
Teclistamab
adult
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
Relapsed/refractory multiple myeloma
injections, subcutaneous
Antineoplastic Agents, Immunological
teclistamab
evaluation of the transparency committee
---
